- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03387163
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure (PROVIDE-HF)
PROVIDE-HF: Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria
- Diagnosis of chronic systolic HF
- Active care by a provider in a healthcare system connected to a PCORnet data partner
- Ability to speak and read English (given the use of the English ePRO technology)
- Newly initiating sacubitril/valsartan (observational sacubitril/valsartan treatment group only - within 1 week of first dose)
- At least a 25% change ACE/ARB dose (including increase and decrease; or initiation or medication switching to another ACEI/ARB) in the last 6 months (comparator group only)
- Reliable access to the internet
Exclusion criteria:
- Inability to provide informed consent
- Life expectancy < 6 months
- For comparator group patients: Physician documentation of planned initiation of sacubitril/valsartan within 12 weeks
Other protocol inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sacubitril/Valsartan
Chronic systolic heart failure patients newly prescribed in mg.
twice daily.
|
commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
|
ACEi/ARB
Chronic systolic heart failure patients receiving ACEi/ARB and no s/v
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline to 12 weeks in the KCCQ
Time Frame: Baseline to weeks 2, 4, 8 and 12
|
Kansas City Cardiomyopathy Questionnaire (KCCQ) - self-administered, 23-item questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life in patients with heart failure.
|
Baseline to weeks 2, 4, 8 and 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Responder analysis for a 5-point improvement in KCCQ to week 12
Time Frame: Baseline to week 12
|
Binary response for a 5-point improvement in KCCQ to week 12
|
Baseline to week 12
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Murmurs
- Heart Failure
- Systolic Murmurs
- Heart Failure, Systolic
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Valsartan
- Sacubitril and valsartan sodium hydrate drug combination
Other Study ID Numbers
- CLCZ696BUS17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure, Systolic
-
Central Hospital, Nancy, FranceUnknown
-
Zensun Sci. & Tech. Co., Ltd.Active, not recruitingChronic Systolic Heart FailureChina
-
Zensun Sci. & Tech. Co., Ltd.TerminatedChronic Systolic Heart FailureChina
-
Hospital Moinhos de VentoTakedaUnknownHeart Failure, Systolic | Systolic Heart Failure | Cardiac FailureBrazil
-
Jiangsu HengRui Medicine Co., Ltd.UnknownChronic Systolic Heart FailureChina
-
Merck KGaA, Darmstadt, GermanyMerck Ltd.Completed
-
University of NebraskaEli Lilly and Company; Daiichi Sankyo, Inc.Completed
-
Abbott Medical DevicesCompletedSystolic Heart FailureAustralia, Hong Kong, Japan
-
University of CincinnatiCompletedSystolic Heart FailureUnited States
-
GlaxoSmithKlineCompletedHeart Failure, CongestiveKorea, Republic of
Clinical Trials on Sacubitril/Valsartan
-
Qingdao Central HospitalNot yet recruitingMyocardial Infarction | HypertensionChina
-
Viatris Inc.Not yet recruiting
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompleted
-
Damanhour UniversityTanta UniversityCompleted
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone SystemUnited States
-
Bio-innova Co., LtdNot yet recruiting
-
Novartis PharmaceuticalsCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States, Canada
-
Viatris Inc.Not yet recruitingBioequivalence StudyThailand
-
University Hospital, ToulouseTerminated